JP Morgan Chase’s Vir Biotechnology VIR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-40,000
Closed -$294K 7757
2024
Q4
$294K Buy
+40,000
New +$316K ﹤0.01% 5305
2023
Q4
Sell
-30,000
Closed -$281K 7892
2023
Q3
$281K Sell
30,000
-85,100
-74% -$1.21M ﹤0.01% 4837
2023
Q2
$2.82M Buy
115,100
+82,100
+249% +$2.06M ﹤0.01% 3287
2023
Q1
$768K Buy
+33,000
New +$844K ﹤0.01% 4223
2022
Q1
Sell
-4,600
Closed -$193K 7055
2021
Q4
$193K Buy
+4,600
New +$180K ﹤0.01% 5383
2021
Q3
Sell
-17,800
Closed -$842K 6833
2021
Q2
$842K Sell
17,800
-7,200
-29% -$327K ﹤0.01% 4401
2021
Q1
$1.28M Buy
+25,000
New +$1.35M ﹤0.01% 4039

Other funds holding VIR

JP Morgan Chase's VIR Position: Q1 2026 in Review

JP Morgan Chase increased its Vir Biotechnology (VIR) stake by 167% in Q1 2026, buying an estimated $5.57M and bringing the position to 1,117,516 shares worth $9.45M. The position accounts for ﹤0.01% of the portfolio, ranked #2735.

JP Morgan Chase first reported a position in VIR in Q4 2019 and has held it in 26 quarters since. The position peaked at $13.3M in Q4 2024. 251 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

  • JP Morgan Chase held 1,117,516 shares of Vir Biotechnology worth $9.45M as of Q1 2026.
  • JP Morgan Chase bought 698,913 Vir Biotechnology shares in Q1 2026, an estimated $5.57M.
  • Vir Biotechnology made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #2735 holding.
  • JP Morgan Chase first reported a position in Vir Biotechnology in Q4 2019 and has held it in 26 quarters since.
  • JP Morgan Chase's Vir Biotechnology position peaked at $13.3M in Q4 2024.
  • 251 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.